A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

Potter, David A.; Thomas, Alexandra; Rugo, Hope S.

doi:10.1158/1078-0432.ccr-21-1133

Cited by 8 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 Similarly, cancer-specific education and communication about the risks associated with COVID versus risk of side effects from COVID vaccines from trusted sources may have alleviated uncertainties or concerns around vaccination. Our findings support recent international research, which also found that breast cancer patients sought information about vaccines from their oncologists 37 and that HPs can assist in the decision making related to COVID-19 vaccines. 20 To support this, once vaccines have been proven to be safe and effective in the general population, clinical trials should focus on vulnerable population groups, such as those with compromised immune systems.…”

Section: Accessibilitysupporting

confidence: 89%

“…Further, research 35 , 39 indicates that education interventions, such as webinars delivered by experts (oncology and disease specialists), can impact patient perspectives regarding COVID‐19 vaccine safety and effectiveness, as well as shift intentions toward vaccination. Potter and colleagues 37 suggest that government agencies and healthcare organizations can also play an important role in media and education campaigns to provide evidence‐based information and prevent the spread of misinformation.…”

Section: Discussionmentioning

confidence: 99%

“…Building on the previous research, the findings reported here suggest that HPs, nongovernment cancer organizations, and government organization all have a role to play in communicating and educating cancer patients about vaccine safety and effectiveness to facilitate vaccine uptake among cancer patients. Communication and education campaigns should be delivered by trusted experts, 35 , 37 , 39 clarify beliefs and values, promote the benefits of vaccination while acknowledging risks and unknowns, correct misinformation, 34 , 37 and use positive framing. 35 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Experiences and perspectives of cancer stakeholders regarding COVID‐19 vaccination

Bartley,

Havard,

Butow

et al. 2022

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Aim The risk of dying from COVID‐19 is higher for those who are older, immune‐compromised, or chronically ill. Vaccines are an effective strategy in reducing mortality and morbidity from COVID‐19. However, for COVID‐19 vaccination programs to reach full potential, vaccines must be taken up by those at greatest risk, such as cancer patients. Understanding the perspectives of all stakeholders involved in cancer patient COVID‐19 vaccine uptake will be critical to ensuring appropriate support, and information is provided to facilitate vaccination. The aim of this research was to explore the longitudinal views of cancer stakeholders regarding COVID‐19 vaccination. Methods Semistructured interviews were conducted with cancer patients ( n = 23), family members ( n = 10), cancer health professionals ( n = 19), and representatives of cancer nongovernment organizations ( n = 7) across Australia 6 and 12 months postrecruitment. Transcripts were thematically analyzed, using an inductive approach. Results All stakeholder groups expressed mostly positive attitudes toward COVID‐19 vaccination, with the following key themes identified: (1) high motivation—vaccination perceived as offering health protection and hope; (2) hesitancy—concern about vaccine hesitancy among the general population, with a minority hesitant themselves; (3) confusion and frustration—regarding the vaccine rollout and patient eligibility; (4) uncertainty—about vaccination in the context of cancer; (5) access to vaccination; and (6) desire for expert individualized advice—on vaccine interaction with cancer treatments. Conclusion These findings highlight the COVID‐19 vaccine concerns and information needs of cancer stakeholders. Policymakers need to provide clear tailored information regarding vaccine eligibility, accessibility, benefits, and risks to facilitate vaccine uptake.

show abstract

Section: Accessibilitysupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Experiences and perspectives of cancer stakeholders regarding COVID‐19 vaccination

Bartley,

Havard,

Butow

et al. 2022

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…Postoperative chemotherapy, radiotherapy, molecular targeted therapy and endocrine therapy for breast cancer patients all need to follow strict treatment norms. During the COVID-19 pandemic, delayed treatment for various reasons may lead to unsatisfactory efficacy, thus affecting patient's disease-free survival and overall survival (8,9). For early-stage breast cancer, patients with delayed chemotherapy over 8 weeks after surgery had a higher risk of all-cause mortality than those with standardized chemotherapy (10).…”

Section: Introductionmentioning

confidence: 99%

Factors Influencing Delayed Treatment in Patients With Breast Cancer During COVID-19 Pandemic

He¹,

Wang²,

Zhao³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe outbreak of coronavirus disease 2019 (COVID-19) has endangered human health and life. This pandemic has changed people's lifestyle and affected the regular delivery of standard cancer treatment. In the present study, we aimed to explore the influencing factors of delayed treatment in patients with breast cancer during COVID-19 pandemic.MethodsThis study was a cross-sectional investigation, and the subjects were patients who were discharged from the department of burn and plastic surgery after February 2020. All participants completed this study's online questionnaire based on the WeChat and Wenjuanxing platforms. Levels of anxiety and depression were measured by the Hospital Anxiety and Depression Scale (HADS). Patients were divided into a delay group and non-delay group according to the occurrence of delayed treatment. Univariate analysis was performed by using the t test or chi-square test. A logistic regression model was employed to determine factors associated with delayed treatment.ResultsThe present study included a total of 397 patients with breast cancer, among whom delayed treatment occurred in 76 patients, accounting for 19.1%. Scores on both the anxiety subscale and depression subscale in delay group were significantly higher than those in non-delay group. Compared with non-delay group, we found that patients in delay group usually had a higher level of education (P = 0.020), worse self-feeling (P = 0.030), poor compliance of medical order (P = 0.042), and a higher prevalence of anxiety (P = 0.004) and depression (P = 0.012). Traffic inconvenience was also an important relevant factor for delayed treatment (P = 0.001). The prevalence of recurrence in delay group was higher than that in non-delay group (P = 0.018). By using logistic multivariate regression analysis, the results revealed that level of education and traffic inconvenience were independent factors influencing delayed treatment in patients with breast cancer during COVID-19 pandemic.ConclusionThe prevalence of delayed treatment in patients with breast cancer during COVID-19 pandemic is relatively high. Our findings reveal several influencing factors closely associated with delayed treatment, which is useful information that will be beneficial for patients to receive standardized therapy by taking targeted measures.

show abstract

“…COVID-19 was rst found in Central China (Wuhan, the capital of Hubei province) at the end of December 2019 [26]. Many reports have explored the relationship of COVID-19 with cancer [27][28][29]. Hoang, T. et al reported that genetic susceptibility of ACE2 and TMPRSS2 in GC was associated with the susceptibility to COVID-19 infection [30].…”

Section: Discussionmentioning

confidence: 99%

Targeting tumor differentiation grade-related genes prognostic signature including COL5A1 based on single-cell RNA-seq in gastric cancer

Wei,

Gao,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Tumor differentiation grade has been shown to be an independent prognostic factor in gastric cancer (GC). Here,we report a novel tumor differentiation grade-related genes signature to predict prognosis and provide new biomarkers in GC. Methods ScRNA-seq profiles of GC were analyzed by seurat package. Core modules and key genes related to tumor differentiation grade were identified through a weighted gene co-expression network analysis (WGCNA) from The Cancer Genome Atlas (TCGA) database. A prognostic signature associated with tumor differentiation grade module including COL5A1 was constructed in GC and validated. Results We identified the single-cell expression profiling and revealed the cell differentiation, cell clusters, marker genes in GC. Functional enrichment analysis revealed that common differentially expressed genes (DEGs) from cell transition trajectory were mainly enriched in neutrophil process. Integrating clinical factors in GC, WGCNA analysis indicated that tumor differentiation grade module was the most significant. We established and validated this signature based on ten tumor differentiation grade-related genes (TNFAIP2, MAGEA3, CXCR4, COL1A1, FN1, VCAN, PXDN, COL5A1, MUC13 and RGS2). Cox regression analysis showed that age, TNM stage and the risk score were significantly associated with prognosis. And then, these genes could predict prognosis in GC. Finally, the hub gene COL5A1 was a prognostic factor, and obviously correlated with B cells memory, dendritic cells activated, macrophages M0, macrophages M2, plasma cells, T cells follicular helper in GC. Conclusions This study reveals a novel tumor differentiation grade-related genes signature predicting prognosis in GC, and COL5A1 represents a promising biomarker for GC immunotherapy.

show abstract

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

Cited by 8 publications

References 42 publications

Experiences and perspectives of cancer stakeholders regarding COVID‐19 vaccination

Experiences and perspectives of cancer stakeholders regarding COVID‐19 vaccination

Factors Influencing Delayed Treatment in Patients With Breast Cancer During COVID-19 Pandemic

Targeting tumor differentiation grade-related genes prognostic signature including COL5A1 based on single-cell RNA-seq in gastric cancer

Contact Info

Product

Resources

About